CSL Limited (CSLLY) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Melbourne, VIC, 호주. 현재 CEO는 Gordon Naylor DipCompSc.
CSLLY 을(를) 보유 IPO 날짜 2009-12-29, 32,698 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $95.92B.
CSL Limited is a global biopharmaceutical company headquartered in Parkville, Australia, with operations across the United States, Europe, China, and other international markets. The company operates through two primary divisions: CSL Behring, which specializes in plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, and neurological conditions, and Seqirus, which focuses on non-plasma biotherapeutics and influenza-related products. CSL Limited researches, develops, manufactures, and distributes a comprehensive portfolio of biopharmaceutical products while also generating revenue through licensing and royalty agreements. Founded in 1916, the company has established itself as a leader in the biopharmaceutical industry through its innovative therapeutic solutions and global market presence.
